Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 16/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25188817 | 0.88 | ALPL (0.56) | MARS1SRD5A2ALPLSMN1; SMN2 | |
| SCHEMBL1413913 | 0.87 | NPC1 (0.55) | ALPLNPC1NR1I2AHRRAB9A | |
| SCHEMBL25183997 | 0.80 | MEN1 (0.49) | MARS1ALPLSMN1; SMN2 | |
| SCHEMBL3682308 | 0.78 | KMO (0.55) | — | |
| SCHEMBL70360 | 0.77 | CA12 (0.53) | ALPL | |
| SCHEMBL14152313 | 0.77 | HCAR2 (0.56) | NPC1RAB9A | |
| SCHEMBL29019950 | 0.76 | MEN1 (0.51) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL69492 | 0.75 | MEN1 (0.58) | ALPLNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4781819 | 0.75 | MAP4K4 (0.59) | MARS1SRD5A2 | |
| SCHEMBL13883208 | 0.74 | HCAR2 (0.47) | ALPLNPC1NR1I2AHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MARS1 55/4885SRD5A2 3080/4885ALPL 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.